Anticancer therapy at end-of-life: A retrospective cohort study
DOI:
https://doi.org/10.2340/1651-226X.2024.22139Keywords:
Neoplasms, End of life care, Palliative care, Quality of health care, Drug therapyAbstract
Background: A significant proportion of patients with incurable cancer receive systemic anticancer therapy (SACT) within their last 30 days of life (DOL). The treatment has questionable benefit, nevertheless is considered a quality indicator of end-of-life (EOL) care. This retrospective cohort study aims to investigate the rates and potential predictors of SACT and factors associated with SACT within the last 30 DOL. The study also evaluates the scope of Eastern Cooperative Oncology Group (ECOG) performance status and the modified Glasgow prognostic score (mGPS) as decision-making tools for oncologists.
Patients and Material: This review of medical records included 383 patients with non-curable cancer who died between July 2018 and December 2019. Descriptive statistics with Chi-squared tests and regression analysis were used to identify factors associated with SACT within the last 30 DOL.
Results: Fifty-seven (15%) patients received SACT within the last 30 DOL. SACT within 30 last DOL was associated with shorter time from diagnosis until death (median 234 days vs. 482, p = 0.008) and ECOG score < 3 30 days prior to death (p = 0.001). Patients receiving SACT during the last 30 DOL were more likely to be hospitalised and die in hospital. ECOG and mGPS score were stated at start last line of treatment only in 139 (51%) and 135 (49%) respectively.
Interpretation: Those with short time since diagnosis tended to receive SACT more frequently the last 30 DOL. The use of mGPS as a decision-making tool is modest, and there is lack in documentation of performance status.
Downloads
References
Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anti-cancer drugs. BMC Syst Biol. 2017;11(Suppl 5):87.
https://doi.org/10.1186/s12918-017-0464-7 DOI: https://doi.org/10.1186/s12918-017-0464-7
Liu W, Zhang L, Xiu Z, et al. Combination of Immune checkpoint inhibitors with chemo-therapy in lung cancer. Onco Targets Ther. 2020;13:7229–41.
https://doi.org/10.2147/OTT.S255491 DOI: https://doi.org/10.2147/OTT.S255491
Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020;2(1).
https://doi.org/10.1093/narcan/zcaa002 DOI: https://doi.org/10.1093/narcan/zcaa002
WHO definition of palliative care. World Health Organization; 2020. Available from: [Cited 5.August 2020] https://www.who.int/cancer/palliative/definition/en/
Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778–84.
https://doi.org/10.1001/jamaoncol.2015.2378 DOI: https://doi.org/10.1001/jamaoncol.2015.2378
Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ. 2014;348(mar04 4):g1219.
https://doi.org/10.1136/bmj.g1219 DOI: https://doi.org/10.1136/bmj.g1219
Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in can-cer: systematic review and network meta-analysis. BMJ. 2018;363:k4226.
https://doi.org/10.1136/bmj.k4226 DOI: https://doi.org/10.1136/bmj.k4226
Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combina-tions: adverse event evaluation and management. ESMO Open. 2019;4(3):e000491.
https://doi.org/10.1136/esmoopen-2019-000491 DOI: https://doi.org/10.1136/esmoopen-2019-000491
Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin On-col. 2003;21(6):1133–8.
https://doi.org/10.1200/JCO.2003.03.059 DOI: https://doi.org/10.1200/JCO.2003.03.059
Crawford GB, Dzierzanowski T, Hauser K, et al. Care of the adult cancer patient at the end of life: ESMO clinical practice guidelines. ESMO Open. 2021;6(4):100225.
https://doi.org/10.1016/j.esmoop.2021.100225 DOI: https://doi.org/10.1016/j.esmoop.2021.100225
Bylicki O, Didier M, Riviere F, Margery J, Grassin F, Chouaid C. Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care. BMJ Support Palliat Care. 2019;9(4):413–24.
https://doi.org/10.1136/bmjspcare-2019-001770 DOI: https://doi.org/10.1136/bmjspcare-2019-001770
Formoso G, Marino M, Guberti M, Grilli RG. End-of-life care in cancer patients: how much drug therapy and how much palliative care? Record linkage study in Nort-hern Italy. BMJ Open. 2022;12(5):e057437.
https://doi.org/10.1136/bmjopen-2021-057437 DOI: https://doi.org/10.1136/bmjopen-2021-057437
Robausch M, Grössmann N, Wild C. Cancer care near the end-of-life in Austria: A retro-spective data analysis. Eur J Cancer Care (Engl). 2021;30(4):e13423.
https://doi.org/10.1111/ecc.13423 DOI: https://doi.org/10.1111/ecc.13423
Riaz F, Gan G, Li F, et al. Adoption of immune checkpoint inhibitors and patterns of care at the end of life. JCO Oncol Pract. 2020;16(11):e1355–e1370.
https://doi.org/10.1200/OP.20.00010 DOI: https://doi.org/10.1200/OP.20.00010
NOU 2017:16 Life and death – palliative care. Oslo: Ministry of Health and Care Services; 2017.
Wakefield D, Bayly J, Selman LE, Firth AM, Higginson IJ, Murtagh FE. Patient empower-ment, what does it mean for adults in the advanced stages of a life-limiting illness: a systematic review using critical interpretive synthesis. Palliat Med. 2018;32(8):1288–304.
https://doi.org/10.1177/0269216318783919 DOI: https://doi.org/10.1177/0269216318783919
Amano K, Maeda I, Shimoyama S, et al. The accuracy of physicians’ clinical predictions of survival in patients with advanced cancer. J Pain Symptom Manage. 2015;50(2):139–46.e1.
https://doi.org/10.1016/j.jpainsymman.2015.03.004 DOI: https://doi.org/10.1016/j.jpainsymman.2015.03.004
Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with ad-vanced cancer based on performance status. J Oncol Pract. 2014;10(5):e335–41.
https://doi.org/10.1200/JOP.2014.001457 DOI: https://doi.org/10.1200/JOP.2014.001457
He L, Li H, Cai J, et al. Prognostic value of the Glasgow prognostic score or modified glas-gow prognostic score for patients with colorectal cancer receiving vari-ous treatments: a systematic review and meta-analysis. Cell Physiol Bi-ochem. 2018;51(3):1237–49.
https://doi.org/10.1159/000495500 DOI: https://doi.org/10.1159/000495500
McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.
https://doi.org/10.1016/j.ctrv.2012.08.003 DOI: https://doi.org/10.1016/j.ctrv.2012.08.003
Proctor MJ, Talwar D, Balmar SM, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical para-meters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer. 2010;103(6):870–6.
https://doi.org/10.1038/sj.bjc.6605855 DOI: https://doi.org/10.1038/sj.bjc.6605855
Zhou T, Hong S, Hu Z, et al. A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumor Biol. 2015;36(1):337–43.
https://doi.org/10.1007/s13277-014-2623-4 DOI: https://doi.org/10.1007/s13277-014-2623-4
Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identi-fies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–24.
https://doi.org/10.1200/JCO.2012.42.8375 DOI: https://doi.org/10.1200/JCO.2012.42.8375
Khaki AR, Li A, Diamantopoulos LN, et al. Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020;126(6):1208–16.
https://doi.org/10.1002/cncr.32645 DOI: https://doi.org/10.1002/cncr.32645
Glisch C, Hagiwara Y, Gilbertson-White S, Gao Y, Lyckholm L. Immune checkpoint inhibi-tor use near the end of life is associated with poor performance status, lower hospice enrollment, and dying in the hospital. Am J Hosp Palliat Care. 2020;37(3):179–84.
https://doi.org/10.1177/1049909119862785 DOI: https://doi.org/10.1177/1049909119862785
O’Sullivan H, Collins D, O’Mahony D, Power D, Bambury R, O’Reilly S. End-of-life care and immune checkpoint inhibitors. J Clin Oncol. 2019;37 (15_suppl):11531.
https://doi.org/10.1200/JCO.2019.37.15_suppl.11531 DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.11531
Nguyen M, Ng Ying Kin S, et al. Anticancer therapy within the last 30 days of life: results of an audit and re-audit cycle from an Australian regional cancer centre. BMC Palliat Care. 2020;19(1):14. DOI: https://doi.org/10.1186/s12904-020-0517-3
Gilbar PJ, McPherson I, Aisthorpe GG, Kondalsamy-Chennakes S. Systemic anticancer therapy in the last 30 days of life: retrospective audit from an Australian Regional Cancer Centre. J Oncol Pharm Pract. 2019;25(3):599–606. DOI: https://doi.org/10.1177/1078155217752077
Bugge C, Kaasa S, Sæther EM, Melberg HO, Sonbo Kristiansen I. What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study. BMJ Open. 2021;11(9):e050564.
https://doi.org/10.1136/bmjopen-2021-050564 DOI: https://doi.org/10.1136/bmjopen-2021-050564
Canavan ME, Wang X, Ascha MS, et al. Systemic anticancer therapy at the end of life-changes in usage pattern in the immunotherapy era. JAMA Oncol. 2022;8(12):1847–9.
https://doi.org/10.1001/jamaoncol.2022.4666 DOI: https://doi.org/10.1001/jamaoncol.2022.4666
Khoja L, McGurk A, O’Hara C, Chow S, Hasan J. Mortality within 30 days following syste-mic anti-cancer therapy, a review of all cases over a 4
year period in a tertiary cancer centre. Eur J Cancer. 2015;51(2):233–40. DOI: https://doi.org/10.1016/j.ejca.2014.11.011
Aida Y, Nakazawa K, Shiozawa T, et al. Small-cell lung cancer treatment of newly diagno-sed patients with poor performance status. Case Rep Oncol. 2019;12(2):613–20.
https://doi.org/10.1159/000501548 DOI: https://doi.org/10.1159/000501548
Guadagnolo BA, Liao KP, Elting L, Giordano S, Buchholz TA, Shih YC. Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol. 2013;31(1):80–7. DOI: https://doi.org/10.1200/JCO.2012.45.0585
Park KR, Lee CG, Tseng YD, et al. Palliative radiation therapy in the last 30 days of life: a sys-tematic review. Radiother Oncol. 2017;125(2): 193–9.
https://doi.org/10.1016/j.radonc.2017.09.016 DOI: https://doi.org/10.1016/j.radonc.2017.09.016
Wu JS, Wong R, Johnston M, Bezjak A, Whelan T. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Ra-diat Oncol Biol Phys. 2003;55(3):594–605. DOI: https://doi.org/10.1016/S0360-3016(02)04147-0
Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Ra-diol). 2012;24(2):112–24.
https://doi.org/10.1016/j.clon.2011.11.004 DOI: https://doi.org/10.1016/j.clon.2011.11.004
Westhoff PG, Verdam MGE, Oort FJ, et al. Course of quality of life after radiation therapy for painful bone metastases: A detailed analysis from the Dutch bone me-tastasis study. Int J Radiat Oncol Biol Phys. 2016;95(5):1391–8.
https://doi.org/10.1016/j.ijrobp.2016.03.032 DOI: https://doi.org/10.1016/j.ijrobp.2016.03.032
Donovan EK, Sienna J, Mitera G, Kumar-Tyagi N, Parpia S, Swaminath A. Single versus multifraction radiotherapy for spinal cord compression: a systematic re-view and meta-analysis. Radiother Oncol. 2019;134:55–66. DOI: https://doi.org/10.1016/j.radonc.2019.01.019
Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation On-cology evidence-based guideline. Pract Radiat Oncol. 2012;2(3):210–25.
https://doi.org/10.1016/j.prro.2011.12.004 DOI: https://doi.org/10.1016/j.prro.2011.12.004
Jordan K, Aapro M, Kaasa S, et al. European Society for Medical Oncology (ESMO) posit-ion paper on supportive and palliative care. Ann Oncol. 2018;29(1):36–43.
https://doi.org/10.1093/annonc/mdx757 DOI: https://doi.org/10.1093/annonc/mdx757
Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice guideline update. J Clin Oncol. 2017;35(1):96–112.
https://doi.org/10.1200/JCO.2016.70.1474 DOI: https://doi.org/10.1200/JCO.2016.70.1474
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.
https://doi.org/10.1056/NEJMoa1000678 DOI: https://doi.org/10.1056/NEJMoa1000678
Triplett DP, LeBrett WG, Bryant AK, et al. Effect of palliative care on aggressiveness of end-of-life care among patients with advanced cancer. J Oncol Pract. 2017;13(9):e760–9.
https://doi.org/10.1200/JOP.2017.020883 DOI: https://doi.org/10.1200/JOP.2017.020883
Smith S, Brick A, O’Hara S, Normand C. Evidence on the cost and cost-effectiveness of palliative care: a literature review. Palliat Med. 2014;28(2):130–50.
https://doi.org/10.1177/0269216313493466 DOI: https://doi.org/10.1177/0269216313493466
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Johnny Singh, Andreas Stensvold, Martin Turzer, Ellen Karine Grov
This work is licensed under a Creative Commons Attribution 4.0 International License.
